MCRIi001-A-1

PB001-OI26

General#

Cell Line

hPSCreg Name MCRIi001-A-1
Alternative name(s)
PB001-OI26
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 7th June 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Murdoch Children's Research Institute (MCRI)
Owner Murdoch Children's Research Institute (MCRI)
Distributors
Derivation country Australia

External Databases

Cellosaurus CVCL_WN06
BioSamples SAMEA5873307

General Information

Publications
* Is the cell line readily obtainable for third parties?
No
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA4966491

Ethics#

Also have a look at the ethics information for the parental line MCRIi001-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Integrated DNA Technologies, Addgene
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation#

General

The source cell information can be found in the parental cell line MCRIi001-A.

Reprogramming method

Vector type None

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Non coated
Feeder cells MEF
Passage method Enzymatically
TrypLE
O2 Concentration 95 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
NEAA 1 %
Glutamax 2 mM
b-mercaptoethanol 0.1 mM
FGF-2 50 ng/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Analysis of Undifferentiated Cells
All analyses published in K. Vlahos, K. Sourris, R. Mayberry, P. McDonald, F.F. Bruveris, J.V. Schiesser, K. Bozaoglu, P.J. Lockhart, E.G. Stanley, A.G. Elefanty, Generation of iPSC lines from peripheral blood mononuclear cells from 5 healthy adults, Stem Cell Res, 34 (2018) 10138. PMID: 30605840

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Molecular karyotype arr(1-22)x2,(XY)x1
Karyotyping method: Molecular karyotyping by SNP array

Other Genotyping (Cell Line)

Genetic Modification#

Disease/phenotype related modifications
Osteogenesis Imperfecta
Gene/mutation described in Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing. Hosseini Far H, Patria YN, Motazedian A, Elefanty AG, Stanley EG, Lamandé SR, Bateman JF. Stem Cell Res. 2019 May;37:101449. doi: 10.1016/j.scr.2019.101449. Epub 2019 Apr 23. PMID: 31075690
Synonyms
  • Osteogenesis Imperfecta
Genetic modifications
Gene knock-in
Gene/mutation described in Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing. Hosseini Far H, Patria YN, Motazedian A, Elefanty AG, Stanley EG, Lamandé SR, Bateman JF. Stem Cell Res. 2019 May;37:101449. doi: 10.1016/j.scr.2019.101449. Epub 2019 Apr 23. PMID: 31075690
CRISPR-associated (CRISPR/Cas) System